Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$2.6B |
| 2 |
Abbott
ABT
|
+$1.29B |
| 3 |
Home Depot
HD
|
+$1.03B |
| 4 |
Devon Energy
DVN
|
+$888M |
| 5 |
PepsiCo
PEP
|
+$880M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$1.6B |
| 2 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$1.5B |
| 3 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$1.34B |
| 4 |
Texas Instruments
TXN
|
+$1.32B |
| 5 |
Coterra Energy
CTRA
|
+$789M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.11% |
| 2 | Financials | 10.61% |
| 3 | Healthcare | 10.33% |
| 4 | Miscellaneous | 9.93% |
| 5 | Industrials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2501
Canadian Solar
CSIQ
$736M
| $4.82M | ﹤0.01% |
301,012
+93,159
| +45% | +$1.49M |
2024 Q2
8 quarters
|
|
2502
Sana Biotechnology
SANA
$754M
| $4.81M | ﹤0.01% |
1,379,181
+13,033
| +1% | +$42K |
2021 Q1
21 quarters
|
|
2503
Energy Vault
NRGV
$560M
| $4.81M | ﹤0.01% |
1,021,618
+347,936
| +52% | +$1.56M |
2022 Q2
16 quarters
|
|
2504
Nova
NVMI
$10.7B
| $4.81M | ﹤0.01% |
8,859
+521
| +6% | +$268K |
2025 Q1
5 quarters
|
|
2505
MiMedx Group
MDXG
$692M
| $4.78M | ﹤0.01% |
1,241,916
-137,249
| -10% | -$501K |
2020 Q4
22 quarters
|
|
2506
Frontline
FRO
$13.2B
| $4.77M | ﹤0.01% |
137,052
-11,175
| -8% | -$411K |
2024 Q2
8 quarters
|
|
2507
Columbia Financial
CLBK
$2.92B
| $4.76M | ﹤0.01% |
493,744
+5,344
| +1% | +$47.2K |
2018 Q2
32 quarters
|
|
2508
Cytek Biosciences
CTKB
$688M
| $4.75M | ﹤0.01% |
1,073,253
-31,348
| -3% | -$134K |
2021 Q3
19 quarters
|
|
2509
Regenxbio
RGNX
$489M
| $4.75M | ﹤0.01% |
396,450
+5,849
| +1% | +$48.5K |
2015 Q4
42 quarters
|
|
2510
Allogene Therapeutics
ALLO
$463M
| $4.73M | ﹤0.01% |
2,274,363
+877,830
| +63% | +$1.93M |
2018 Q4
30 quarters
|
|
2511
IBEX
IBEX
$602M
| $4.73M | ﹤0.01% |
155,765
-18,196
| -10% | -$542K |
2021 Q1
21 quarters
|
|
2512
UroGen Pharma
URGN
$1.87B
| $4.72M | ﹤0.01% |
128,370
+39,904
| +45% | +$1.08M |
2023 Q2
12 quarters
|
|
2513
Lexicon Pharmaceuticals
LXRX
$716M
| $4.7M | ﹤0.01% |
1,956,775
+645,477
| +49% | +$1.26M |
2013 Q2
52 quarters
|
|
2514
Village Super Market
VLGEA
$655M
| $4.67M | ﹤0.01% |
110,803
-33,584
| -23% | -$1.44M |
2013 Q2
52 quarters
|
|
2515
DELISTED
Northfield Bancorp
NFBK
| $4.67M | ﹤0.01% |
317,068
+4,256
| +1% | +$60.2K |
2013 Q2
52 quarters
|
|
2516
Bullish
BLSH
$4.86B
| $4.63M | ﹤0.01% |
197,443
-72,674
| -27% | -$2.53M |
2025 Q4
2 quarters
|
|
2517
Kearny Financial
KRNY
$576M
| $4.61M | ﹤0.01% |
487,405
+8,783
| +2% | +$72.3K |
2013 Q2
52 quarters
|
|
2518
Corsair Gaming
CRSR
$1.52B
| $4.6M | ﹤0.01% |
476,103
+48,875
| +11% | +$378K |
2020 Q4
22 quarters
|
|
2519
Grindr
GRND
$2.69B
| $4.59M | ﹤0.01% |
319,248
-17,700
| -5% | -$229K |
2023 Q1
13 quarters
|
|
2520
Sprout Social
SPT
$686M
| $4.57M | ﹤0.01% |
604,992
+110,440
| +22% | +$719K |
2020 Q1
25 quarters
|
|
2521
JELD-WEN Holding
JELD
$116M
| $4.55M | ﹤0.01% |
3,033,817
-1,228,291
| -29% | -$1.89M |
2017 Q1
37 quarters
|
|
2522
Phathom Pharmaceuticals
PHAT
$560M
| $4.55M | ﹤0.01% |
419,094
+10,079
| +2% | +$115K |
2019 Q4
26 quarters
|
|
2523
Ascendis Pharma A/S
ASND
$14.8B
| $4.54M | ﹤0.01% |
+17,014
| New | +$3.97M |
2026 Q2
0 quarters
|
|
2524
AIAI Holdings
AIAI
$228M
| $4.54M | ﹤0.01% |
+326,205
| New | +$4.72M |
2026 Q2
0 quarters
|
|
2525
Silvercorp Metals
SVM
$2.25B
| $4.53M | ﹤0.01% |
447,260
+13,857
| +3% | +$167K |
2026 Q1
1 quarter
|
|
Similar funds
Charles Schwab's Q2 2026 Portfolio in Review
As of Q2 2026, Charles Schwab held 3,591 positions worth $751B, up 15% from $654B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Charles Schwab's Q2 2026 filing shows 136 new, 2,145 increased, 1,132 reduced and 153 closed positions. Its largest new stake was Honeywell Aerospace: 2,031,187 shares worth $449M. The largest sale was Qualcomm, an estimated $1.6B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2026 buy was Honeywell Aerospace: 2,031,187 shares worth $449M.
- Charles Schwab added most to Schwab US Large-Cap Growth ETF in Q2 2026, an estimated $2.6B increase.
- Charles Schwab's biggest Q2 2026 reduction was Qualcomm, cutting an estimated $1.6B.
- Charles Schwab fully exited Coterra Energy in Q2 2026, selling an estimated $789M.
- Charles Schwab's ten largest holdings make up 22% of its $751B portfolio in Q2 2026.
- Charles Schwab opened 136 new positions and closed 153 in Q2 2026.
- Charles Schwab's portfolio value rose 15% quarter-over-quarter to $751B.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.